COVID-19 vaccine program boosts revenues of German pharmaceutical company BioNTech


  • World
  • Wednesday, 12 Aug 2020

BERLIN, Aug. 11 (Xinhua) -- Revenues of German pharmaceutical company BioNTech in the second quarter (Q2) of 2020 reached 41.8 million euros (49.3 million U.S. dollars), compared with 25.8 million euros in Q2 last year, the firm announced on Tuesday.

Revenues from collaboration agreements went up as well because of new projects with U.S. company Pfizer and China's Fosun Pharma "as part of the company's BNT162 vaccine program against COVID-19," according to BioNTech.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In World

13 dead in central Senegal road accident
Indigenous people protest Brazil not protecting ancestral lands
Canada launches U.S. dollar global bond to bolster foreign reserves
Algeria hosts 23rd "Chinese Bridge" language competition for university students
Trump's three US Supreme Court appointees thrash out immunity claim
Alphabet reports revenues, net income jump in first quarter
Weekly storage of natural gas in U.S. increases: EIA
Intel reports revenue increase in first quarter
Microsoft reports Q3 results with net income, revenue increases
Finland's finance ministry downgrades growth forecast for 2024

Others Also Read